Immedica Pharma to acquire Neurocrine Group for $65m.

Immedica Pharma, a company specializing in rare disease pharmaceuticals, agreed to acquire Neurocrine Group, a company focused on rare endocrinology therapies, for $65m. “This acquisition supports our ambition to reach more patients living with rare diseases while continuing to build a sustainable and focused business,” Anders Edvell, Immedica CEO.